NCT04312841View on ClinicalTrials.gov

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

November 24, 2023

Study Completion Date

April 9, 2024

Conditions
B-Cell Prolymphocytic LeukemiaChronic Lymphocytic LeukemiaPeripheral T-Cell LymphomaPrimary Cutaneous T-Cell Non-Hodgkin LymphomaSezary SyndromeT-Cell Prolymphocytic Leukemia
Interventions
DRUG

Letermovir

Given PO

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT04312841 - Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab | Biotech Hunter | Biotech Hunter